These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Baricitinib for COVID-19: a suitable treatment? - Authors' reply. Richardson PJ; Corbellino M; Stebbing J Lancet Infect Dis; 2020 Sep; 20(9):1013-1014. PubMed ID: 32251639 [No Abstract] [Full Text] [Related]
24. Impact of COVID-19 on maternal and child health - Authors' reply. Chou VB; Carter ED; Sawadogo-Lewis T Lancet Glob Health; 2020 Oct; 8(10):e1260. PubMed ID: 32758431 [No Abstract] [Full Text] [Related]
25. Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic. Authors' reply. King DS; Trudgill NJ; Adderley NJ Aliment Pharmacol Ther; 2020 Jun; 51(12):1442-1443. PubMed ID: 32406090 [No Abstract] [Full Text] [Related]
26. Antihypertensive drugs and risk of COVID-19? - Authors' reply. Fang L; Karakiulakis G; Roth M Lancet Respir Med; 2020 May; 8(5):e32-e33. PubMed ID: 32222169 [No Abstract] [Full Text] [Related]
27. Reply to a Comment about the Article Published in Acta Med Port 2020; Apr 27; doi:10.20344/amp.13928. Nogueira PJ; De Araújo Nobre M; Nicola PJ; Furtado C; Vaz Carneiro A Acta Med Port; 2020 Jul; 33(7-8):534-535. PubMed ID: 32519664 [No Abstract] [Full Text] [Related]
28. Authors' Reply: Open tracheostomy for COVID-19-positive patients: A method to minimize aerosolization and reduce risk of exposure. Rhee P J Trauma Acute Care Surg; 2020 Nov; 89(5):e156-e157. PubMed ID: 32796438 [No Abstract] [Full Text] [Related]
30. Treatments for COVID-19: emerging drugs against the coronavirus - reply. Potì F Acta Biomed; 2020 Jun; 91(3):ahead of print. PubMed ID: 32921741 [No Abstract] [Full Text] [Related]
31. Risk factors for in-hospital mortality in patients with cancer and COVID-19 - Authors' reply. Yang K; Sheng Y; Wu B; Wu G Lancet Oncol; 2020 Sep; 21(9):e408. PubMed ID: 32888458 [No Abstract] [Full Text] [Related]
32. Predictors of arrhythmia other than QT interval prolongation and the use of β-blocker therapy in the coronavirus disease 2019 pandemic. Authors' reply. Biernacka EK; Kosior DA; Zienciuk-Krajka A; Miszczak-Knecht M; Kempa M; Przybylski A Kardiol Pol; 2020 Aug; 78(7-8):796-797. PubMed ID: 32844612 [No Abstract] [Full Text] [Related]
35. Authors' response re: From the frontlines of COVID-19-How prepared are we as obstetricians: a commentary. Chua MSQ; Lee JCS; Sulaiman S; Tan HK BJOG; 2020 Jul; 127(8):1041-1042. PubMed ID: 32372552 [No Abstract] [Full Text] [Related]
36. Clinical Characteristics of Covid-19 in China. Reply. Guan WJ; Zhong NS N Engl J Med; 2020 May; 382(19):1861-1862. PubMed ID: 32220206 [No Abstract] [Full Text] [Related]
37. Reply Letter - COVID-19 (Novel Coronavirus 2019) - Recent trends. Kannan S; Shaik Syed Ali Pakeer P; Sheeza Ali A; Hemalatha K Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6482-6483. PubMed ID: 32633333 [No Abstract] [Full Text] [Related]
38. Authors' Reply. Farkash EA; Wilson AM; Jentzen JM J Am Soc Nephrol; 2020 Sep; 31(9):2225-2226. PubMed ID: 32792369 [No Abstract] [Full Text] [Related]
39. Errors in Tracing Coronavirus SARS-CoV-2 Transmission Using a Maximum Likelihood Tree. Comment on "A Snapshot of SARS-CoV-2 Genome Availability up to April 2020 and its Implications: Data Analysis". Forster P; Forster L JMIR Public Health Surveill; 2020 Nov; 6(4):e23542. PubMed ID: 33174859 [No Abstract] [Full Text] [Related]